A Jatoi1, S E Schild2, N Foster3, G T Henning4, K J Dornfeld5, P J Flynn6, T R Fitch2, S R Dakhil7, K M Rowland8, P J Stella4, G S Soori9, A A Adjei10. 1. Mayo Clinic Rochester, Rochester, MN. Electronic address: jatoi.aminah@mayo.edu. 2. Mayo Clinic Arizona, Scottsdale, AZ. 3. Mayo Clinic Rochester, Rochester, MN. 4. Michigan Cancer Consortium, Ann Arbor, MI. 5. Duluth City Clinical Oncology Program, Duluth, MN. 6. Metro-Minnesota Community Oncology Program, St Louis Park, MN. 7. Wichita Community Clinical Oncology Program, Wichita, KS. 8. Carle Cancer Center City Clinical Oncology Program, Urbana, IL. 9. Missouri Valley Cancer Consortium, Omaha, NE. 10. Roswell Park Cancer Institute, Buffalo, NY, USA.
Abstract
BACKGROUND: Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC. PATIENTS AND METHODS: Older patients [≥ 65 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2] or younger patients (performance status of 2) received cetuximab 400 mg/m(2) i.v. on day 1 followed by weekly cetuximab 250 mg/m(2) i.v. with concomitant radiation of 6000 cGy in 30 fractions. The primary end point was the percentage who lived 11+ months. RESULTS: This 57-patient cohort had a median age (range) of 77 years (60-87), and 12 (21%) had a performance status of 2. Forty of 57 (70%) lived 11+ months, thus exceeding the anticipated survival rate of 50%. The median survival was 15.1 months [95% confidence interval (CI) 13.1-19.3 months], and the median time to cancer progression was 7.2 months (95% CI 5.8-8.6 months). No treatment-related deaths occurred, but 31 patients experienced grade 3+ adverse events, most commonly fatigue, anorexia, dyspnea, rash, and dysphagia, each of which occurred in <10% of patients. CONCLUSION: This combination merits further study in this group of patients.
BACKGROUND:Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC. PATIENTS AND METHODS: Older patients [≥ 65 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2] or younger patients (performance status of 2) received cetuximab 400 mg/m(2) i.v. on day 1 followed by weekly cetuximab 250 mg/m(2) i.v. with concomitant radiation of 6000 cGy in 30 fractions. The primary end point was the percentage who lived 11+ months. RESULTS: This 57-patient cohort had a median age (range) of 77 years (60-87), and 12 (21%) had a performance status of 2. Forty of 57 (70%) lived 11+ months, thus exceeding the anticipated survival rate of 50%. The median survival was 15.1 months [95% confidence interval (CI) 13.1-19.3 months], and the median time to cancer progression was 7.2 months (95% CI 5.8-8.6 months). No treatment-related deaths occurred, but 31 patients experienced grade 3+ adverse events, most commonly fatigue, anorexia, dyspnea, rash, and dysphagia, each of which occurred in <10% of patients. CONCLUSION: This combination merits further study in this group of patients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Steven E Schild; Philip J Stella; Susan M Geyer; James A Bonner; William L McGinnis; James A Mailliard; Jeffery Brindle; Aminah Jatoi; James R Jett Journal: J Clin Oncol Date: 2003-07-21 Impact factor: 44.544
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245
Authors: Steven E Schild; Sumithra J Mandrekar; Aminah Jatoi; William L McGinnis; Phillip J Stella; Richard L Deming; James R Jett; Yolanda I Garces; Katie L Allen; Alex A Adjei Journal: Cancer Date: 2007-07-15 Impact factor: 6.860
Authors: F Couñago; A Rodríguez; P Calvo; J Luna; J L Monroy; B Taboada; V Díaz; N Rodríguez de Dios Journal: Clin Transl Oncol Date: 2016-04-22 Impact factor: 3.405
Authors: E Aaron Runkle; Hongtao Zhang; Zheng Cai; Zhiqiang Zhu; Barry L Karger; Shiaw-Lin Wu; Donald M O'Rourke; Zhaocai Zhou; Qiang Wang; Mark I Greene Journal: Exp Mol Pathol Date: 2012-09-27 Impact factor: 3.362
Authors: Ritsuko Komaki; Rebecca Paulus; George R Blumenschein; Walter J Curran; Francisco Robert; Juliette Thariat; Maria Werner-Wasik; Hak Choy; Fred R Hirsch; Kie Kian Ang Journal: Radiother Oncol Date: 2014-07-16 Impact factor: 6.280
Authors: Yuhchyau Chen; James Moon; Kishan J Pandya; Derick H M Lau; Karen Kelly; Fred R Hirsch; Laurie E Gaspar; Mary Redman; David R Gandara Journal: Front Oncol Date: 2013-08-28 Impact factor: 6.244